Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19

NCT04732949 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

623

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19

Interventions

DRUG: SNG001
DRUG: Placebo

Sponsor

Synairgen Research Ltd.